2024
Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023
DeCuir J, Surie D, Zhu Y, Lauring A, Gaglani M, McNeal T, Ghamande S, Peltan I, Brown S, Ginde A, Steinwand A, Mohr N, Gibbs K, Hager D, Ali H, Frosch A, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Khan A, Busse L, Duggal A, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Safdar B, Mosier J, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Rhoads J, Swan S, Johnson C, Lewis N, Ellington S, Dawood F, McMorrow M, Self W, Network F. Effectiveness of Original Monovalent and Bivalent COVID‐19 Vaccines Against COVID‐19‐Associated Hospitalization and Severe In‐Hospital Outcomes Among Adults in the United States, September 2022–August 2023. Influenza And Other Respiratory Viruses 2024, 18: e70027. PMID: 39496339, PMCID: PMC11534416, DOI: 10.1111/irv.70027.Peer-Reviewed Original ResearchConceptsCOVID-19-associated hospitalizationIn-hospital outcomesVaccine effectivenessMonovalent dosesAbsolute VETest-negative case-control designInvasive mechanical ventilationCOVID-19 vaccineMultivariate logistic regressionSevere COVID-19Case patientsCase-control designControl patientsMechanical ventilationUnvaccinated patientsPatientsMonovalent vaccineCOVID-19-like illnessDoseCOVID-19 vaccine effectivenessBivalent vaccineLogistic regressionAdmission dateVaccineHospitalSeverity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults
Surie D, Yuengling K, DeCuir J, Zhu Y, Lauring A, Gaglani M, Ghamande S, Peltan I, Brown S, Ginde A, Martinez A, Mohr N, Gibbs K, Hager D, Ali H, Prekker M, Gong M, Mohamed A, Johnson N, Srinivasan V, Steingrub J, Leis A, Khan A, Hough C, Bender W, Duggal A, Bendall E, Wilson J, Qadir N, Chang S, Mallow C, Kwon J, Exline M, Shapiro N, Columbus C, Vaughn I, Ramesh M, Mosier J, Safdar B, Casey J, Talbot H, Rice T, Halasa N, Chappell J, Grijalva C, Baughman A, Womack K, Swan S, Johnson C, Lwin C, Lewis N, Ellington S, McMorrow M, Martin E, Self W. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Network Open 2024, 7: e244954. PMID: 38573635, PMCID: PMC11192181, DOI: 10.1001/jamanetworkopen.2024.4954.Peer-Reviewed Original ResearchConceptsInvasive mechanical ventilationRespiratory syncytial virusSeverity of RSV diseaseInfluenza diseaseVaccinated patientsIn-hospital deathUnvaccinated patientsRSV diseaseSyncytial virusClinical decision-makingComposite of invasive mechanical ventilationOutcome of invasive mechanical ventilationSeverity of respiratory syncytial virusLaboratory-confirmed respiratory syncytial virusHospitalized US adultsInfluenza vaccination statusVaccination statusAcute respiratory illnessMultivariate logistic regressionCenters for Disease Control and PreventionSeverity of COVID-19Disease Control and PreventionInfluenza infectionInfluenza severityClinical outcomes
2023
2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023
DeCuir J, Zhu Y, Gaglani M, Ginde A, Mohr N, Gibbs K, Hager D, Frosch A, Mohamed A, Johnson N, Steingrub J, Peltan I, Martin E, Bender W, Wilson J, Qadir N, Mallow C, Kwon J, Exline M, Lauring A, Columbus C, Vaughn I, Safdar B, Chappell J, Baughman A, Womack K, Swan S, McMorrow M, Self W, Surie D. 2083. Waning of Bivalent mRNA Vaccine Effectiveness Against COVID-19-associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years – IVY Network, 20 U.S. States, September 8, 2022-April 1, 2023. Open Forum Infectious Diseases 2023, 10: ofad500.153. PMCID: PMC10677158, DOI: 10.1093/ofid/ofad500.153.Peer-Reviewed Original ResearchCOVID-19-associated hospitalizationRelative vaccine effectivenessVaccine effectivenessBooster doseSARS-CoV-2Hospitalized adultsIllness onsetDays of receiptCOVID-19 vaccination seriesCOVID-19-like illnessAdditional booster dosesAsahi Kasei PharmaMRNA vaccine effectivenessMultivariable logistic regressionHuman Services (HHS) regionsCase-control analysisUnvaccinated patientsVaccination seriesBooster dosesImmunization PracticesMRNA vaccinationAdults AgedRespiratory virusesAntigen testAdmission date